PharmaCyte Biotech, Inc. (PMCB) › Cash & EquivalentsPharmaCyte Biotech, Inc. (PMCB) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2010: $7162011: $57.2K2012: $15.7K2013: $199.3K2022: $85.40M2023: $68.04M2024: $50.18M2025: $15.17M$15.17M2010Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$15.17M-69.8%2024$50.18M-26.2%2023$68.04M-20.3%2022$85.40M—2013$199.3K+1167.6%2012$15.7K-72.5%2011$57.2K+7889.0%2010$716—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share